US 2003/0144196 A1Published application

Activated T lymphocyte nucleic acid sequences and polypeptides encoded by same

OwnerMichael A. Bowen, Joshua Fingerinventors

Life of this patent

Estimating the term…

Loading patent…

Abstract

The invention provides novel human polynucleotides unique to, associated with, or highly expressed activated T-lymphocytes (Regulated in Activated T Lymphocytes). The novel polynucleotides were derived from a cDNA subtraction library constructed from human peripheral blood T lymphocytes activated with antibodies against CD3 and CD28 cell surface antigens. The invention also provides for the use and production of the polynucleotides, antisense polynucleotides, amino acid sequences, and/or polypeptides, peptides, and antigenic epitopes thereof encoded by these polynucleotides, and to compositions and methods comprising the polynucleotides and polypeptides and peptides identified herein for modulation of an immune response and for the diagnosis, prevention, or treatment of disorders associated with aberrant cellular development and differentiation including cancer and inflammation, graft vs. host disease, transplantation rejection and autoimmune disease.

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:21 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:
XXXXX, which is hybridizable to SEQ ID NO:21;
(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:22 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:
XXXXX, which is hybridizable to SEQ ID NO:21;
(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:22 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
XXXXX, which is hybridizable to SEQ ID NO:21;
(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:22 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:
XXXXX, which is hybridizable to SEQ ID NO:21;
(e) a polynucleotide encoding a polypeptide of SEQ ID NO:22 or the cDNA sequence included in ATCC Deposit No:
XXXXX, which is hybridizable to SEQ ID NO:21, having immune modulatory activity;
(f) an isolated polynucleotide comprising nucleotides 1030 to 1677 of SEQ ID NO:21, wherein said nucleotides encode a polypeptide corresponding to amino acids 3 to 218 of SEQ ID NO:22 minus the first and second amino acids;
(g) an isolated polynucleotide comprising nucleotides 1027 to 1677 of SEQ ID NO:21, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 218 of SEQ ID NO:22 minus the start methionine;
(h) an isolated polynucleotide comprising nucleotides 1024 to 1677 of SEQ ID NO:21, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 218 of SEQ ID NO:22 including the start methionine;
(i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:21;
and
(j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

13 more elements

Abstract

Claims19